28 April 2021 - Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers and insurers last year paid anywhere from two to four times as much for 20 brand name medicines than what were paid in Australia, Canada, and France.
For instance, the cost for a one month supply of the Xarelto, which is used to combat blood clots, was $272 in the U.S. for those with some form of health insurance, but between $64 and $78 in the other countries.
A three month supply of the Imbruvica cancer pill cost an estimated $13,809 in the U.S., while cancer patients in the other three countries paid between $6,011 and $7,120.